Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 11, Issue 12, Pages 889-890Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd3909
Keywords
-
Ask authors/readers for more resources
As cancer therapy progresses through the development of molecularly targeted drugs, the focus of Phase I trials needs to shift towards investigating end points that could guide more effective trial design, dosing and choice of tumour setting for Phase II studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
